XORTX Partners with Mount Sinai`s Icahn School of Medicine on US-based Clinical Trial in COVID-19
(WorldNews China)

CALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) - XORTX Therapeutics Inc. (`XORTX` or the `Company`) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a partnership with the Icahn School of Medicine at Mount Sinai, New York to study the incidence of Acute Kidney Injury and Hyperuricemia in patients hospitalized with COVID-19. This clinical study in nearly 4,000 patients with COVID-19 builds upon unpublished observations from over 1,100 individuals, where greater than 60% of individuals with acute kidney injury had elevated uric acid levels above the normal range. This partnership with...